Market Overview

Alliqua Enters License Agreement with Celgene, Celgene to Purchase 1.672M Shares of Alliqua at $3.59/Share

7 Biggest Price Target Changes For Friday
Mid-Afternoon Market Update: RH Gains After Strong Q4 Results; Quorum Health Shares Plummet

Alliqua (OTC: ALQA) entered into a
licensing agreement with Celgene Cellular Therapeutics (“CCT”), a
subsidiary of Celgene Corporation (NASDAQ: CELG) (“Celgene”), whereby
Alliqua received the right to develop and market the advanced wound care
products Biovance® and Extracellular Matrix (ECM).
Concurrently with the license agreement, Alliqua entered into an
agreement with Celgene to sell to Celgene 1,672,474 shares of common
stock of Alliqua, at a purchase price of $3.59 per share and a five year
warrant to purchase an additional 836,237 shares of common stock at an
exercise price of $5.69, in exchange for $6.0 million. In connection
with this agreement to invest in Alliqua's securities, Celgene received
a right to appoint a director to Alliqua's Board

See full press release

Posted-In: News Guidance Contracts Management Insider Trades M&A Global


Related Articles (CELG + ALQA)

View Comments and Join the Discussion!